A likelihood‐based approach to assessing frequency of pathogenicity among variants of unknown significance in susceptibility genes
- 29 October 2020
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 40 (3) , 593-606
Abstract
Commercialized multigene panel testing brings unprecedented opportunities to understand germline genetic contributions to hereditary cancers. Most genetic testing companies classify the pathogenicity of variants as pathogenic, benign, or variants of unknown significance (VUSs). The unknown pathogenicity of VUSs poses serious challenges to clinical decision‐making. This study aims to assess the frequency of VUSs that are likely pathogenic in disease‐susceptibility genes. Using estimates of probands' probability of having a pathogenic mutation (ie, the carrier score) based on a family history probabilistic risk prediction model, we assume the carrier score distribution for probands with VUSs is a mixture of the carrier score distribution for probands with positive results and the carrier score distribution for probands with negative results. Under this mixture model, we propose a likelihood‐based approach to assess the frequency of pathogenicity among probands with VUSs, while accounting for the existence of possible pathogenic mutations on genes not tested. We conducted simulations to assess the performance of the approach and show that under various settings, the approach performs well with very little bias in the estimated proportion of VUSs that are likely pathogenic. We also estimate the positive predictive value across the entire range of carrier scores. We apply our approach to the USC‐Stanford Hereditary Cancer Panel Testing cohort, and estimate the proportion of probands that have VUSs in BRCA1/2 that are likely pathogenic to be 10.12% [95%CI: 0%, 43.04%]. This approach will enable clinicians to target high‐risk patients who have VUSs, allowing for early prevention interventions.Keywords
This publication has 27 references indexed in Scilit:
- Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer historiesCancer Genetics, 2017
- Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk AssessmentJAMA Oncology, 2015
- Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genesBreast Cancer Research and Treatment, 2014
- Assessment of computational methods for predicting the effects of missense mutations in human cancersBMC Genomics, 2013
- Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood RatiosCancer Informatics, 2008
- A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer–Predisposition GenesThe American Journal of Human Genetics, 2007
- Genetic and Histopathologic Evaluation ofBRCA1andBRCA2DNA Sequence Variants of Unknown Clinical SignificanceCancer Research, 2006
- Classification of Missense Mutations of Disease GenesJournal of the American Statistical Association, 2005
- The BOADICEA model of genetic susceptibility to breast and ovarian cancerBritish Journal of Cancer, 2004
- BayesMendel: an R Environment for Mendelian Risk PredictionStatistical Applications in Genetics and Molecular Biology, 2004